

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
 US Department of Commerce  
 United States Patent and Trademark  
 Office, PCT  
 2011 South Clark Place Room  
 CP2/5C24  
 Arlington, VA 22202  
 ETATS-UNIS D'AMERIQUE  
 in its capacity as elected Office

<b>Date of mailing (day/month/year)</b> 22 June 2001 (22.06.01)	
<b>International application No.</b> PCT/EP00/09292	<b>Applicant's or agent's file reference</b> PG4159/PCT
<b>International filing date (day/month/year)</b> 22 September 2000 (22.09.00)	<b>Priority date (day/month/year)</b> 01 October 1999 (01.10.99)
<b>Applicant</b> ANDERSON, Gregor, John, McLennan et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
 06 April 2001 (06.04.01)

☐ in a notice effecting later election filed with the International Bureau on:  
 \_\_\_\_\_

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Olivia TEFY Telephone No.: (41-22) 338.83.38
---	---

# PCT

## REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty

For receiving office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference  
(if desired) (12 characters maximum) PG4159/ PCT

Box No. I	TITLE OF INVENTION
	Patient data monitoring system

Box No. II	APPLICANT
<p>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below).</p> <p>Glaxo Group Limited Glaxo Wellcome House Berkeley Avenue Greenford, Middlesex UB6 0NN GB</p>	
<p>State (i.e. country) of nationality: GB</p> <p>State (i.e. country) of residence: GB</p>	
<p>This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input checked="" type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box</p>	
<p><input type="checkbox"/> This person is also inventor.</p> <p>Telephone No. 020 7493 4060</p> <p>Facsimile No. 020 8966 8838</p> <p>Teleprinter No. 25456</p>	

Box No. III	FURTHER APPLICANTS AND/OR (FURTHER) INVENTORS
<p>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</p> <p>ANDERSON, Gregor John McLennan Glaxo Wellcome plc. Park Road Ware, Herts. SG12 ODP GB</p>	
<p>State (i.e. country) of nationality: GB</p> <p>State (i.e. country) of residence: GB</p>	
<p>This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input checked="" type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box</p>	
<p><input type="checkbox"/> applicant only</p> <p><input checked="" type="checkbox"/> applicant and inventor</p> <p><input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)</p>	

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV	AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE
<p>The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: <input checked="" type="checkbox"/> agent <input type="checkbox"/> common representative</p>	
<p>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country).</p> <p>PIKE, Christopher Gerard Pike &amp; Co., Hayes Loft, 68A Hayes Place Marlow, Buckinghamshire SL7 2BT, GB</p>	
<p>Telephone No.: 01628-471869</p> <p>Facsimile No.: 01628-471878</p> <p>Teleprinter No.:</p>	
<p><input type="checkbox"/> Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.</p>	

## Continuation of Box No. III FURTHER APPLICANTS AND/OR (FURTHER) INVENTORS

*If none of the following sub-boxes is used, this sheet is not to be included in the request.*

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

BONNEY, Stanley George  
Glaxo Wellcome plc.  
Park Road  
Ware, Herts.  
SG12 ODP  
GB

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (i.e. country) of nationality:  
GB

State (i.e. country) of residence:  
GB

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

JONES, Anthony Patrick  
Glaxo Wellcome plc.  
Park Road  
Ware, Herts.  
SG12 ODP  
GB

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (i.e. country) of nationality:  
GB

State (i.e. country) of residence:  
GB

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

ROBERTSON, Duncan  
Glaxo Wellcome plc.  
Park Road  
Ware, Herts.  
SG12 ODP  
GB

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (i.e. country) of nationality:

State (i.e. country) of residence:

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (i.e. country) of nationality:

State (i.e. country) of residence:

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on a continuation sheet.

**Box No. V DESIGNATION OF STATES**

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

**Regional Patent**

- ☒ **AP** ARIPO Patent: GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT.
- ☒ **EA** Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP** European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA** OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line).

National Patent (if other kind of protection or treatment desired, specify on dotted line):

- |   |   |
|---|---|
| <input checked="" type="checkbox"/> <b>AE</b> United Arab Emirates                  | <input checked="" type="checkbox"/> <b>LR</b> Liberia                                   |
| <input checked="" type="checkbox"/> <b>AL</b> Albania                               | <input checked="" type="checkbox"/> <b>LS</b> Lesotho                                   |
| <input checked="" type="checkbox"/> <b>AM</b> Armenia                               | <input checked="" type="checkbox"/> <b>LT</b> Lithuania                                 |
| <input checked="" type="checkbox"/> <b>AT</b> Austria                               | <input checked="" type="checkbox"/> <b>LU</b> Luxembourg                                |
| <input checked="" type="checkbox"/> <b>AU</b> Australia                             | <input checked="" type="checkbox"/> <b>LV</b> Latvia                                    |
| <input checked="" type="checkbox"/> <b>AZ</b> Azerbaijan                            | <input checked="" type="checkbox"/> <b>MA</b> Morocco                                   |
| <input checked="" type="checkbox"/> <b>BA</b> Bosnia and Herzegovina                | <input checked="" type="checkbox"/> <b>MD</b> Republic of Moldova                       |
| <input checked="" type="checkbox"/> <b>BB</b> Barbados                              | <input checked="" type="checkbox"/> <b>MG</b> Madagascar                                |
| <input checked="" type="checkbox"/> <b>BG</b> Bulgaria                              | <input checked="" type="checkbox"/> <b>MK</b> The former Yugoslav Republic of Macedonia |
| <input checked="" type="checkbox"/> <b>BR</b> Brazil                                | <input checked="" type="checkbox"/> <b>MN</b> Mongolia                                  |
| <input checked="" type="checkbox"/> <b>BY</b> Belarus                               | <input checked="" type="checkbox"/> <b>MW</b> Malawi                                    |
| <input checked="" type="checkbox"/> <b>CA</b> Canada                                | <input checked="" type="checkbox"/> <b>MX</b> Mexico                                    |
| <input checked="" type="checkbox"/> <b>CH and LI</b> Switzerland and Liechtenstein  | <input checked="" type="checkbox"/> <b>NO</b> Norway                                    |
| <input checked="" type="checkbox"/> <b>CN</b> China                                 | <input checked="" type="checkbox"/> <b>NZ</b> New Zealand                               |
| <input checked="" type="checkbox"/> <b>CR</b> Costa Rica                            | <input checked="" type="checkbox"/> <b>PL</b> Poland                                    |
| <input checked="" type="checkbox"/> <b>CU</b> Cuba                                  | <input checked="" type="checkbox"/> <b>PT</b> Portugal                                  |
| <input checked="" type="checkbox"/> <b>CZ</b> Czech Republic                        | <input checked="" type="checkbox"/> <b>RO</b> Romania                                   |
| <input checked="" type="checkbox"/> <b>DE</b> Germany                               | <input checked="" type="checkbox"/> <b>RU</b> Russian Federation                        |
| <input checked="" type="checkbox"/> <b>DK</b> Denmark                               | <input checked="" type="checkbox"/> <b>SD</b> Sudan                                     |
| <input checked="" type="checkbox"/> <b>DM</b> Dominica                              | <input checked="" type="checkbox"/> <b>SE</b> Sweden                                    |
| <input checked="" type="checkbox"/> <b>EE</b> Estonia                               | <input checked="" type="checkbox"/> <b>SG</b> Singapore                                 |
| <input checked="" type="checkbox"/> <b>ES</b> Spain                                 | <input checked="" type="checkbox"/> <b>SI</b> Slovenia                                  |
| <input checked="" type="checkbox"/> <b>FI</b> Finland                               | <input checked="" type="checkbox"/> <b>SK</b> Slovakia                                  |
| <input checked="" type="checkbox"/> <b>GB</b> United Kingdom                        | <input checked="" type="checkbox"/> <b>SL</b> Sierra Leone                              |
| <input checked="" type="checkbox"/> <b>GD</b> Grenada                               | <input checked="" type="checkbox"/> <b>TJ</b> Tajikistan                                |
| <input checked="" type="checkbox"/> <b>GE</b> Georgia                               | <input checked="" type="checkbox"/> <b>TM</b> Turkmenistan                              |
| <input checked="" type="checkbox"/> <b>GH</b> Ghana                                 | <input checked="" type="checkbox"/> <b>TR</b> Turkey                                    |
| <input checked="" type="checkbox"/> <b>GM</b> Gambia                                | <input checked="" type="checkbox"/> <b>TT</b> Trinidad and Tobago                       |
| <input checked="" type="checkbox"/> <b>HR</b> Croatia                               | <input checked="" type="checkbox"/> <b>TZ</b> United Republic of Tanzania               |
| <input checked="" type="checkbox"/> <b>HU</b> Hungary                               | <input checked="" type="checkbox"/> <b>UA</b> Ukraine                                   |
| <input checked="" type="checkbox"/> <b>ID</b> Indonesia                             | <input checked="" type="checkbox"/> <b>UG</b> Uganda                                    |
| <input checked="" type="checkbox"/> <b>IL</b> Israel                                | <input checked="" type="checkbox"/> <b>US</b> United States of America                  |
| <input checked="" type="checkbox"/> <b>IN</b> India                                 | <input checked="" type="checkbox"/> <b>UZ</b> Uzbekistan                                |
| <input checked="" type="checkbox"/> <b>IS</b> Iceland                               | <input checked="" type="checkbox"/> <b>VN</b> Viet Nam                                  |
| <input checked="" type="checkbox"/> <b>JP</b> Japan                                 | <input checked="" type="checkbox"/> <b>YU</b> Yugoslavia                                |
| <input checked="" type="checkbox"/> <b>KE</b> Kenya                                 | <input checked="" type="checkbox"/> <b>ZA</b> South Africa                              |
| <input checked="" type="checkbox"/> <b>KG</b> Kyrgyzstan                            | <input checked="" type="checkbox"/> <b>ZW</b> Zimbabwe                                  |
| <input checked="" type="checkbox"/> <b>KP</b> Democratic People's Republic of Korea |   |
| <input checked="" type="checkbox"/> <b>KR</b> Republic of Korea                     |   |
| <input checked="" type="checkbox"/> <b>KZ</b> Kazakhstan                            |   |
| <input checked="" type="checkbox"/> <b>LC</b> Saint Lucia                           |   |
| <input checked="" type="checkbox"/> <b>LK</b> Sri Lanka                             |   |

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

- ☒ **AG** Antigua and Barbuda
- ☒ **BZ** Belize
- ☒ **DZ** Algeria
- ☒ **MZ** Mozambique


**Precautionary Designation Statement:** In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)

<b>Box No. VI PRIORITY CLAIM</b>		<input type="checkbox"/> Further priority claims are indicated in the Supplemental Box		
		Where earlier application is		
Filing Date of Earlier Application (day/month/year)	Number of earlier application	national application: country	regional application: * regional Office	international application: receiving Office
item (1) (01.10.99) 1 October 1999	9923273.8	GB		
item (2) (09.05.00) 9 May 2000	0011029.6	GB		
item (3) (22.08.00) 22 August 2000	0020541.9	GB		

☐ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s):  
 \* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.

<b>Box No. VII INTERNATIONAL SEARCHING AUTHORITY</b>	
Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used): ISA/	Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority): Date (day/month/year)      Number      Country (or regional office)

<b>Box. VIII CHECK LIST; LANGUAGE OF FILING</b>	
This international application contains the following number of sheets: request : 4 description (excluding sequence listing part) : 30 claims : 12 abstract : 1 drawings : 8 sequence listing part of description : Total number of sheets : 55	This international application is accompanied by the item(s) marked below: 1. <input checked="" type="checkbox"/> fee calculation sheet 2. <input checked="" type="checkbox"/> separate signed power of attorney (1) 3. <input checked="" type="checkbox"/> copy of general power of attorney; reference number, if any: 4. <input checked="" type="checkbox"/> statement explaining lack of signature 5. <input checked="" type="checkbox"/> priority documents (3) identified in Box No. VI as item(s): 1,2,3 6. <input type="checkbox"/> translation of international application into (language): 7. <input type="checkbox"/> separate indications concerning deposited microorganism or other biological material 8. <input type="checkbox"/> nucleotide and/or amino acid sequence listing in computer readable form 9. <input type="checkbox"/> other (specify):
Figure of the drawings which should accompany the abstract: None	Language of filing of the international application: English

<b>Box No. IX SIGNATURE OF APPLICANT OR AGENT</b>	
Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).	
Christopher Gerard Pike Agent for the Applicants	

<b>For receiving Office use only</b>		2. Drawings <input type="checkbox"/> received: <input type="checkbox"/> not received:
1. Date of actual receipt of the purported international application	3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):	5. International Searching Authority specified by the applicant: ISA/	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid

Date of receipt of the record copy by the International Bureau	<b>For International Bureau use only</b>
--	--

# PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>PG4159/PCT</b>	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. <b>PCT/EP00/09292</b>	International filing date (day/month/year) <b>22/09/2000</b>	Priority date (day/month/year) <b>01/10/1999</b>
International Patent Classification (IPC) or national classification and IPC <b>G06F19/00</b>		
Applicant <b>GLAXO GROUP LIMITED</b>		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 6 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  <b>06/04/2001</b>	Date of completion of this report  <b>30.10.2001</b>
Name and mailing address of the international preliminary examining authority:   <b>European Patent Office</b> <b>D-80298 Munich</b> <b>Tel. +49 89 2399 - 0 Tx: 523656 epmu d</b> <b>Fax: +49 89 2399 - 4465</b>	Authorized officer  <b>Barraco, G</b>  Telephone No. <b>+49 89 2399 2172</b> <div data-bbox="1380 1837 1534 1984" data-label="Image"> </div>

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/09292

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

### Description, pages:

1-30 as published

### Claims, No.:

1-77 as published

### Drawings, sheets:

1/8-8/8 as published

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/09292

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. Statement

Novelty (N)	Yes:	Claims	1-77
	No:	Claims	
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-77
Industrial applicability (IA)	Yes:	Claims	1-77
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

## VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:  
**see separate sheet**

## VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**



**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Reference is made to the following documents :

D1: US-A-5 924 074

D2: EP-A-0 884 670

The various definitions of the invention given in independent Claims 1, 62, 72, 74, 76 and 77 are such that the claims as a whole are not clear and concise, contrary to Article 6 PCT. The claims should be recast to include only the minimum necessary number of independent claims in any one category, with dependent claims as appropriate (Rule 6.4(a)-(c) PCT).

In the present case it is considered appropriate to use only one independent claim in any category, with dependencies of claims clearly defined, see in this regard also Rule 6.4 PCT.

The various features of the independent claims and their distributions, are so different that doubts remain for the reader on which are the features essential for the performance of the system/method for which protection will be sought.

In particular, the separate independent claiming of the system as a whole and the network computer system for use with the system as a whole and the corresponding methods appears not appropriate and " unconcise " in the present case.

Furthermore, insofar as the present text can be understood, the subject-matter of above independent Claims does not involve an inventive step, and therefore does not satisfy the criterion set forth in Article 33(3) PCT.

The subject-matter of independent claims appears to be directed to a system/method for collecting maintaining and retrieving medical data adopting the technique

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP00/09292

maintaining in separate databases the patient data ( and patient identifiers) and the conditions data ( with medications and practice guidelines ), and then allowing only authorized accesses to the databases, via network entry points.

It is noted that this technique is already known in the art and is disclosed for example in the electronic medical records system known from D1, cf . D1 : Abstract and from column 2, line 21 to column 3, line 42 and figures 1, 4, 13,14, 24 with related corresponding explaining text.

Therefore a clarified independent claim defining an implementation of this known technique is at least not inventive and does not satisfy the criterion set forth in Art. 33(3) PCT.

It is furthermore noted that a claim defining said implementation and evidencing as characterizing feature the selective access and selective authorization ( i.e. defining different levels of security level to be applied for accessing the databases ) is also considered not inventive, being the authorized access of the databases by different types of users ( physician, nurses, healthcare providers etc. ) suggested in various passages of D1, cf. for example, in particular, D1: II. SUMMARY on column 14.

Dependent claims do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of inventive step being considered obvious operational features of a system as the one known from D1.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP00/09292

**Re Item VII**

**Certain defects in the international application**

2. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1 as well as D2, which also discloses an analogous medical database maintenance system/method, are not mentioned in the description, nor are these documents identified therein.

**Re Item VIII**

**Certain observations on the international application**

3. Over the unclarities objected, as per point 1. above, it is noted that reference signs in parentheses are not inserted in the claims to increase their intelligibility, Rule 6.2(B) PCT.

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number  
WO 01/26020 A1

(51) International Patent Classification<sup>7</sup>: G06F 19/00, 1/00

(21) International Application Number: PCT/EP00/09292

(22) International Filing Date:  
22 September 2000 (22.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9923273.8 1 October 1999 (01.10.1999) GB  
0011029.6 9 May 2000 (09.05.2000) GB  
0020541.9 22 August 2000 (22.08.2000) GB

(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ANDERSON, Gregor, John, McLennan [GB/GB]; Glaxo Wellcome

plc., Park Road, Ware, Herts. SG12 0DP (GB). BONNEY, Stanley, George [GB/GB]; Glaxo Wellcome plc., Park Road, Ware, Herts. SG12 0DP (GB). JONES, Anthony, Patrick [GB/GB]; Glaxo Wellcome plc., Park Road, Ware, Herts. SG12 0DP (GB). ROBERTSON, Duncan [—/GB]; Glaxo Wellcome plc., Park Road, Ware, Herts. SG12 0DP (GB).


(74) Agent: PIKE, Christopher, Gerard; Pike & Co., Hayes Loft, 68A Hayes Place, Marlow, Buckinghamshire SL7 2BT (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: PATIENT DATA MONITORING SYSTEM



(57) Abstract: There is provided a system for collecting and providing selective access to medical data relevant to plural patients having related medical conditions. The system comprises a network computer system (50) and associated with the network computer system (50) a first patient-specific database and a second condition-specific database. Remote from the network computer system (50) there are provided plural patient electronic data collectors (10), each for collecting patient data relevant to a particular patient's medical condition. Associated with each system patient electronic data collector (10), there is a communicator (40) for communicating with an entypoint to the network computer system (50) to enable transfer of said patient data to the first patient-specific database and to the second condition-specific database. The system includes a first secure access gateway permitting access to the first patient-specific database in response to a first user authorisation command and a second secure access gateway permitting access to the second condition-specific database in response to a second user authorisation command.



IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *With international search report.*

## INTERNATIONAL SEARCH REPORT

PCT/EU/00/09292

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 G06F19/00 G06F1/00

According to International Patent Classification (IPC) or to both national classification and IPC

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G06F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y  A	US 5 924 074 A (EVANS JAE A) 13 July 1999 (1999-07-13)	1-7, 9-11, 14-26, 28, 32-43, 46,47, 50, 62-70, 72-77 8,27, 29-31, 44,45, 48,49,71
	column 4, line 64 -column 15, line 67 figures 1,4,13,14,24 --- -/-	

**X** Further documents are listed in the continuation of box C.

**X** Patent family members are listed in annex.

\* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

**"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone**

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*& document member of the same patent family

Date of the actual completion of the international search

10 January 2001

Date of mailing of the international search report

17/01/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer \_\_\_\_\_

**Jacobs, P**

# INTERNATIONAL SEARCH REPORT

Inten      Application No  
PCT/EP 00/09292

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 884 670 A (INT COMPUTERS LTD) 16 December 1998 (1998-12-16)	1-7, 9-11, 14-26, 28, 32-43, 46, 47, 50, 62-70, 72-77
A	abstract column 1, line 5 -column 6, line 30 figures 1,2 claims 1,4,6	29-31
A	WO 99 41682 A (JOHNSON DAVID WAYNE ;SOUTHERN RES INST (US); DEAN ALAN HOYT (US);) 19 August 1999 (1999-08-19)  abstract page 3, line 15 -page 9, line 5 figures 1-3	1-12, 14-19, 25, 28, 32-77
A	US 5 338 157 A (BLOMQUIST MICHAEL L) 16 August 1994 (1994-08-16) abstract column 5, line 59 -column 19, line 62 figures 1,2	1-19, 25, 28, 32-77

# INTERNATIONAL SEARCH REPORT

information on patent family members

Inter. Application No

PCT/EP 00/09292

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5924074 A	13-07-1999	AU 4603497 A WO 9813783 A	17-04-1998 02-04-1998
EP 0884670 A	16-12-1998	NONE	
WO 9941682 A	19-08-1999	AU 2762899 A	30-08-1999
US 5338157 A	16-08-1994	AU 693073 B AU 4840093 A AU 714459 B AU 6474498 A AU 6474598 A CA 2143436 A EP 1018347 A EP 0744973 A JP 8500515 T WO 9405355 A US 5485408 A US 6024539 A	25-06-1998 29-03-1994 06-01-2000 02-07-1998 02-07-1998 17-03-1994 12-07-2000 04-12-1996 23-01-1996 17-03-1994 16-01-1996 15-02-2000